study reveals that SGLT2 inhibitors consistently lower the risk of major adverse cardiovascular events by 9% across various patient groups, especially impacting cardiovascular death reduction, highlighting their broad therapeutic potential beyond diabetes management.
Long-Acting Injectable Helped Adults With Schizophrenia Remain Relapse-Free
A study showed that 96% of patients with schizophrenia remained relapse-free with every-6-month dosing of the long-acting injectable paliperidone palmitate (Invega Hafyera) through up to
October 18, 2023